Astellas R&D Day Pioneering science to change tomorrow March 31, 2026 1 ©2026 ASTELLAS PHARMA INC. AND ITS AFFILIATES. Cautionary statement regarding forward-looking information In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas Pharma. These statements are based on management's current assumptions and beliefs in light of the information c ...

Core Insights - Coherus Oncology is transitioning into an innovative oncology company focused on overcoming immune resistance in cancer, with a strong emphasis on its commercial PD-1 therapy LOQTORZI and new pipeline assets acquired from Surface Oncology [5][22]. Group 1: LOQTORZI Overview - LOQTORZI is described as a next-generation PD-1 therapy with high-affinity binding, effective in low PD-L1 cancers, and is currently labeled for low PD-L1 esophageal cancer in the EU [1]. - Sales of LOQTORZI increased significantly from $19.1 million in 2024 to $40.8 million in 2025, with expectations of reaching $15–16 million per quarter in 2026 and targeting a 70% market share by 2028, equating to approximately $175 million annualized [7][10]. - The company is pursuing a $33 billion opportunity based on ongoing trials in the U.S. [2]. Group 2: Financial Developments - Coherus completed the sale of UDENYCA to Intas for an upfront payment of $483 million, with additional payments expected, which will support the company's financial stability [3]. - The company has paid down nearly $480 million in debt and retained $250 million on its balance sheet to fund development efforts [4][7]. Group 3: Pipeline Progress - The pipeline includes tagmokitug, a CCR8 Treg depleter, and casdozokitug, an IL-27 blocker, with promising clinical outcomes reported, including a 38% overall response rate in first-line hepatocellular carcinoma [6][17]. - Tagmokitug is being studied in various cancers, including head and neck and gastrointestinal cancers, and is expected to enter prostate cancer studies in collaboration with Johnson & Johnson [12][15]. - Coherus is also exploring additional collaborations for tagmokitug and casdozokitug, aiming for ex-U.S. licensing to manage development costs [21].

Advancing Antibody Drug Conjugates With Novel Immuno-Oncology Payloads Forward-Looking Statements This presentation includes expressed or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), about the Akari Therapeutics, Plc (the "Company") that involve risks and uncertainties relating to future events and the future performance of the Company. Actual events or re ...

Financial Performance & Strategy - Astellas' FY25 sales revenue reached ¥2 trillion[8] - Core operating profit margin for FY25 was 20.5%[7, 8] - The company aims to elevate profitability and invest in strategic brands and pipeline[14] - Astellas is implementing a disciplined cost optimization plan targeting ¥150 billion ($1.03 billion) in savings between FY24-27[46, 47] R&D and Pipeline - R&D expenses represent 17% of revenue[8] - The company is progressing R&D pipelines in synergy with Strategic Brands[20] - ASP3082 (setidegrasib) + mFOLFIRINOX shows objective responses in PDAC patients with KRAS G12D mutations, with an ORR of 58.3% (7/12) and a DCR of 83.3% (10/12)[35, 37] - ASP2138 in combination with Standard of Care drives striking anti-tumor activity in Gastric/GEJ adenocarcinoma irrespective of Claudin 18.2 Expression, with an ORR of 62.5% (15/24) and a 12-week DCR of 100.0% (6/6)[42, 45] Key Products & Market Access - Over 172 million patients in >70 countries are reached by Astellas products[8] - >1,300,000 men (FY2012-2024) treated globally with XTANDI[10]

Core Insights - OSR Holdings, Inc. has appointed Dr. Andreas Niethammer as the new CEO of Vaximm AG, effective December 1, 2025, marking a significant leadership change in the company [1][4] - Dr. Niethammer is recognized for his expertise in oncology and has been instrumental in developing Vaximm's oral T-cell immunotherapy platform, particularly the lead candidate VXM01 targeting VEGFR-2 [2][5] - The company plans to integrate its anti-angiogenic immune activation platform with viral oncolysis technologies to enhance its immuno-oncology offerings, with a strategic collaboration expected to be announced soon [3][4] Company Overview - Vaximm AG is a Swiss-German biotechnology company focused on oral T-cell vaccination, utilizing live, attenuated bacterial vectors to induce immune responses against tumors [5] - The lead therapeutic candidate, VXM01, has shown clinical activity and safety across multiple cancer types, particularly in pancreatic cancer and glioblastoma [2][5] - OSR Holdings, Inc. is a global healthcare holding company that supports biomedical innovations across various sectors, including immuno-oncology and regenerative biologics [6]

TriKE® Technology and Pipeline - GT Biopharma's TriKE® platform utilizes camelid nanobodies to target NK cells to tumor cells, activating them via CD16A and IL-15 [5, 13] - The company has 6+ pipeline assets in preclinical development, targeting both solid tumors and hematological malignancies [5] - GTB-3650, a 2nd generation TriKE® targeting CD33, has an IND accepted in June 2024, with the first patient dosed on January 21, 2025 [5, 7] - GTB-7550 TriKE® is in development for the treatment of lupus and other autoimmune disorders [5, 37] - GTB-3550, the first generation TriKE® targeting CD33, showed proof of concept in Phase 1 in AML patients, reducing CD33+ bone marrow blast levels by 333%-636% in some patients [5, 26] Financial Status - As of March 31, 2025, GT Biopharma had $25 million in cash and short-term investments, with a debt-free balance sheet [5] - An additional $54 million in cash was raised on May 12, 2025 [5]

Akari Therapeutics Overview - Akari Therapeutics focuses on innovating antibody-drug conjugates (ADCs) as immuno-oncology therapies [3] - The company's lead payload, PH1, is a spliceosome inhibitor that causes cell death and activates the immune system [10] - Akari is developing novel target ADCs with the PH1 payload applicable to colon, lung, breast, and prostate cancers [12] PH1 Payload Mechanism and Advantages - PH1's mechanism of action generates mis-spliced transcripts leading to immunogenic neoantigens, 9 times greater than DM4 [23, 25] - PH1 overcomes resistance mechanisms and has reduced off-target toxicity due to its linker being engineered for intracellular release [17] - Preclinical data shows synergy between PH1 payload ADCs and checkpoint inhibitors [16] ADC Pipeline and Development - Akari's proprietary PH1 payload can build an entire ADC pipeline, with the ability to design several uniquely targeted ADCs in parallel [33] - AKTX-101 (Trop2 target) is ready for GMP manufacturing/GLP tox studies [36] - AKTX-102 is being developed against a novel target with potential in lung, colon, and breast cancers [36] Market Opportunity and Deal Flow - There is a strong need for ADCs with new payload mechanisms beyond current ADC therapies, especially in lung cancer [13] - Early-stage ADC deal flow shows continued momentum, with deals ranging from $20 million to $400 million upfront and total deal highlights reaching up to $1.34 billion [8] - One licensing deal for EO-1022 (HER3) reached $368 million in upfront and clinical, regulatory, and commercial milestone payments [8]